San Diego’s Orexigen Therapeutics Inc. and its marketing partner Takeda Pharmaceutical Co. Ltd. on Tuesday abruptly terminated a study into how Orexigen’s Contrave obesity drug might affect the cardiovascular system.

In a joint news release, Orexigen and Takeda said the study – which was halted after only 50 percent of the data was compiled – was “not being terminated due to a finding of superiority or harm.”

Orexigen and Takeda said they are still evaluating the cardiovascular events that occurred in the study and will present their findings in a scientific forum once that process is completed.

By noon on Wall Street, Orexigen (Nasdaq: OREX) shares were hovering from 8 percent to 11 percent below the opening price.